89bio Raises $288M to Pioneer Breakthrough Therapies for Liver and Cardio-Metabolic Diseases

89bio is thrilled to announce a landmark funding milestone, having raised $288 million to further our mission of transforming the treatment landscape for liver and cardio-metabolic diseases. As a clinical-stage biopharmaceutical company headquartered in San Francisco, with vibrant research operations in Herzliya, Israel, 89bio has been at the forefront of developing pioneering therapies that prioritize the patient above all else. This new capital injection will significantly accelerate our work on BIO89-100, our lead product candidate—a specifically engineered glycoPEGylated analog of FGF21 designed to treat nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). Encouraging results from our recent Phase 1b/2a trials have shown that BIO89-100 exhibits a robust safety and tolerability profile, with weekly and biweekly dosing regimens delivering notable reductions in liver fat and key lipid markers among NASH patients, while we continue our Phase 2 trial for SHTG. The funding will further empower our innovative research and clinical programs, bolstering our commitment to developing therapies that address unmet medical needs. At 89bio, our culture is defined by core values that include a relentless focus on putting patients first, upholding the highest standards of integrity and authenticity, collaborating as a united team, and maintaining a passion for scientific inquiry and rational decision-making. With this significant investment, we are more energized than ever to advance our clinical pipeline and deliver life-changing treatments to patients around the globe.